Fulgent Genetics, Inc.

FLGT Healthcare Diagnostics & Research

Fulgent Genetics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $322.7 million, up 13.8% from fiscal 2024. In the quarter to June 2026, revenue grew 4.38%, EPS fell 69.4% and free cash flow grew 25.4%, each against the same quarter a year earlier.

19.81 1.53 −7.17%
Market cap
$587.2M
P/E
0.0×
Fwd P/E
−5.8×
Dividend yield
—
F-score
4/9
Altman Z
5.63
Beneish M
−2.35
Dividend safety
n/a
Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
P/E ratio
0.00 0.00 0.00 0.00 5.97 5.81 6.48 0.00 0.00 0.00
Piotroski F-Score
6 5 4 6 6 5 5 4 6 4
P/S ratio
8.36 4.01 2.67 7.42 2.80 2.98 1.49 3.02 1.97 2.51
Altman Z-Score
26.24 14.85 11.69 24.02 8.36 19.45 6.78 5.91 4.68 5.63
P/FCF ratio
243.81 0.00 0.00 55.67 11.21 5.75 3.92 156.59 0.00 0.00
Altman Z″-Score (non-manufacturers)
15.65 18.66 19.55 14.64 11.73 18.68 16.78 14.58 15.74 14.32
P/Operating CF
121.90 (60.46) 73.25 (2,080.57) 8.81 38.37 27.79 58.42 22.32 (10.35)
Beneish M-Score
(0.29) (2.97) (2.66) (1.53) 8.62 (1.34) (3.70) (2.55) (1.99) (2.35)
P/B ratio
2.81 1.39 1.11 2.92 2.08 2.54 0.73 0.77 0.49 0.73
Price to Tangible BV
2.81 1.39 1.11 2.92 2.08 2.74 0.95 0.90 0.54 0.80
EV/Sales
7.22 2.59 1.22 6.63 2.13 2.55 0.67 1.62 1.13 1.53
EV/EBITDA
61.37 0.00 0.00 120.87 3.06 3.64 1.93 0.00 0.00 0.00
EV/Operating CF
29.97 36.48 (38.45) 39.11 6.39 4.70 1.65 17.37 15.26 (4.85)
EV/FCF
210.52 (12.06) (7.40) 49.77 8.52 4.91 1.78 84.22 (16.96) (3.97)
Quick Ratio
7.61 10.16 13.51 9.35 3.71 5.60 6.57 6.51 4.49 4.95
Current Ratio
7.88 10.98 14.44 9.96 4.02 5.81 7.13 6.96 4.85 6.48
Net Debt/EBITDA
(9.70) 19.14 11.89 (15.84) (0.97) (0.63) (2.37) 7.99 4.73 4.66
Debt/Assets
0.00% 0.00% 0.00% 0.00% 2.14% 1.18% 1.08% 0.00% 0.00% 0.00%
Debt/Equity
0.00 0.00 0.00 0.00 0.03 0.01 0.01 0.00 0.00 0.00
Asset Turnover
0.57 0.33 0.38 0.46 1.07 1.00 0.46 0.22 0.23 0.27
Operating CF/Net income
(0.82) (0.53) 0.12 (13.42) 0.66 1.06 1.77 (0.16) (0.49) 1.68
Capex/Depreciation
(3.06) (2.55) (1.15) (0.53) (9.20) (1.28) (0.49) (0.15) (2.06) (1.19)
Interest Coverage
— (7.62) (8.77) (0.49) 193.44 519.96 176.24 (400.67) 434.81 (1,214.61)
ROE
(17.94%) (4.62%) (10.65%) (0.61%) 65.72% 58.48% 11.77% (13.97%) (3.78%) (5.41%)
ROA
(16.74%) (4.36%) (10.09%) (0.58%) 54.31% 51.27% 10.76% (12.80%) (3.48%) (4.97%)
ROIC
1.71% (7.86%) (15.75%) (0.49%) 63.62% 57.83% 14.71% (17.23%) (5.30%) (7.39%)
Return on Tangible Assets
(18.40%) (6.75%) (12.96%) (1.05%) 49.41% 89.18% 23.09% (32.38%) (11.06%) (10.47%)
Average Days of Receivables
87.16 78.05 101.68 73.55 159.13 51.08 31.11 64.53 88.87 95.88
Research and Development Expense of Revenue
19.47% 22.55% 25.92% 20.10% 2.75% 2.44% 4.67% 14.33% 17.22% 16.71%
Selling, General and Administrative Expense of Revenue
38.73% 50.39% 47.73% 37.85% 7.15% 7.57% 24.23% 45.11% 43.87% 49.60%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00 0.00 0.07 0.21 0.13 0.08 0.07
Share Based Compensation of Revenue
25.47% 11.31% 10.79% 9.87% 1.93% 1.60% 5.27% 14.84% 15.69% 12.27%
Graham Net Nets
0.15 0.40 0.65 0.13 0.33 0.17 0.55 0.47 0.47 0.55
Graham Number
0.00 0.00 0.00 0.00 70.16 124.26 67.01 0.00 0.00 0.00
Earnings Yield
(3.98%) (3.58%) (9.89%) (0.11%) 16.74% 17.21% 15.43% (19.26%) (7.63%) (7.46%)
Free Cash Flow Yield
0.41% (5.36%) (6.15%) 1.80% 8.92% 17.40% 25.48% 0.64% (3.39%) (15.36%)
Revenue per Share
1.33 1.06 1.19 1.74 18.58 33.75 20.57 9.71 9.38 10.48
Operating CF per Share
0.32 0.08 (0.04) 0.29 6.20 18.31 8.42 0.91 0.70 (3.30)
Capex per Share
(0.28) (0.30) (0.16) (0.06) (1.55) (0.81) (0.61) (0.72) (1.32) (0.73)
Free Cash Flow per Share
0.05 (0.23) (0.20) 0.23 4.65 17.51 7.81 0.19 (0.63) (4.04)
Cash per Share
1.52 1.49 1.73 1.51 13.19 15.32 17.48 14.24 8.54 10.92
Shareholders Equity per Share
3.97 3.05 2.85 4.42 25.09 39.65 42.19 38.05 37.35 35.96
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
3.97 3.05 2.85 4.42 25.09 39.65 42.19 38.05 37.35 35.96
Free Cash Flow
0.63 (4.02) (3.51) 4.34 105.51 514.80 235.16 5.57 (18.94) (124.21)
Working Capital
22.82 29.93 36.81 33.36 393.50 506.65 539.77 434.83 280.67 465.52
Capital Expenditures
(3.78) (5.36) (2.83) (1.18) (35.12) (23.78) (18.36) (21.43) (40.00) (22.57)
Net Current Asset Value
22.58 29.92 36.79 31.10 392.54 499.12 511.70 405.80 262.77 443.68
EV/EBIT
143.79 0.00 0.00 0.00 3.10 3.74 2.34 0.00 0.00 0.00
Capex to Sales
0.21 0.29 0.13 0.04 0.08 0.02 0.03 0.07 0.14 0.07
Price to Operating Income
166.52 0.00 0.00 0.00 4.07 4.38 5.17 0.00 0.00 0.00
Other line items
Depreciation/Fixed assets
0.20 0.29 0.38 0.37 0.10 0.30 0.46 1.71 0.18 0.17
Cash ROIC
0.83% (4.99%) (4.27%) 3.90% 11.94% 31.55% 12.98% 0.36% (1.37%) (8.61%)
Accounts Receivable Turnover
5.64 4.48 4.29 5.20 4.43 6.15 6.46 5.57 4.72 4.20
Accounts Payable Turnover
4.38 3.53 6.29 9.75 6.40 9.18 11.57 9.61 10.45 10.36
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Average Days of Payables
149.65 89.17 44.80 40.91 107.65 34.71 33.44 30.34 38.03 35.50
Days of Inventory on Hand
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Average Receivables
3.24 4.18 4.98 6.25 95.21 161.38 95.83 51.94 60.08 76.89
Average Payables
1.54 2.42 1.70 1.45 14.03 23.49 21.79 19.23 16.86 18.51
Average Assets
31.94 57.61 55.54 71.33 394.61 989.59 1,332.39 1,310.69 1,227.65 1,216.74
Average Common Equity
29.81 54.33 52.67 66.96 326.08 867.63 1,217.88 1,201.58 1,131.22 1,117.94

Fold the line items

Columns are period end dates